Jpmorgan Chase & CO Nektar Therapeutics Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NKTR
# of Institutions
26Shares Held
16.8MCall Options Held
17.2KPut Options Held
0-
Black Rock Inc. New York, NY15.2MShares$358 Million0.0% of portfolio
-
Morgan Stanley New York, NY584KShares$13.8 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL327KShares$7.71 Million0.0% of portfolio
-
Vista Wealth Management Group, LLC51.5KShares$1.22 Million0.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC32.2KShares$758,7870.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $4.42B
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...